FDA pauses Swedish diabetes company's phase III trial plans
The share price of biotech company Diamyd Medical is falling after the the US Food and Drug Administration postponed its planned phase III trial because of several outstanding questions.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
The US Food and Drug Administration (FDA) has put Diamyd Medical's planned phase III trial under a 'partial clinical hold'.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk starts crucial trial of obesity tablet
For subscribers
.jpg&w=384&q=75)
